B. J. Spalding, Bio/Technology 10, 24-29 (1992). |
Nasar J. Qureshi et al. AIDS, 4, 553-558 (1990). |
O'Shea et al. Science vol. 243 (1/89) 538-542.* |
Wild et al., “PNAS, USA” 89, pp 10537-10541 (11/92).* |
Crowl et al., “Cell” 41, pp 979-986 (1985).* |
Leff, Bio Word Today, 1994 vol. 5 No. 210 pp.—1 & 5.* |
Hammer et al, J. of Acq. Immunol Def. Syn., (1994) 7 (Suppl): 524-537.* |
Saag et al., J. of Acq. Immunol Def. Syn., (1994) 7 (Suppl.):52-511.* |
Davey et al., Proc. Natl. Acad. Sci, vol. 90, (1993) pp. 5608-5612.* |
Richman et al, J. of Virology, (1994) vol. 68, No. 3, pp. 1660-1666.* |
Crowl et al. HTLV-III env Gene Products Synthesized in E Coli are Recognized by Antibodies Present in the Sera of Aids Patients Cell 41(3) 979-86 Jul. 1985.* |
Gallaher et al. Aids Research and Human Retrovirus, 5(4) (1969) 431-440.* |
Detwart et al. AIDS Research and Human Retroviruses 6, 6 (1990) 703-706.* |
Buckland et al. J Gen. Virol. 73(7) 1992 1703-1707.* |
ASM News Jul. 1990 vol. 56(7) 368.* |
Hammer, S.M. et al., 1994, “Issues in Combination Antiretroviral Therapy: A Review”, J. Acq. Imm. Def. Syn. 7(Suppl. 2):S24-S37. |
Richman, D.D. et al., 1994, “Nevirapine Resistance Mutations of Human Immunodeficiency Virus Type 1 Selected During Therapy”, J. Virol. 68:1660-1666. |
Saag, M.S. et al., 1994, “Pathogenicity and Diversity of HIV and Implications for Clinical Management: A Review”, J. Acq. Imm. Def. Syn. 7(Suppl. 2):S2-S11. |
Davey, R.T. et al., 1993, “Plasma Viremia as a Sensitive Indicator of the Antiretroviral Activity of L-697,661”, Proc. Natl. Acad. Sci. (USA) 90:5608-5612. |
Buckland, R. et al., 1992, “A Leucine Zipper Structure Present in the Measles Virus Fusion Protein is not Required for its Tetramerization but is Essential for Fusion”, J. Gen. Virol. 73:1703-1707. |
Dubay J.W. et al., 1992, “Mutations in the Leucine Zipper of the Human Immunodeficiency Virus Type 1 Transmembrane Glycoprotein Affect Fusion and Infectivity”, J. Virol. 66:4748-4756. |
Neurath, A.R. et al., 1992, “Synthetic Peptides and Anti-Peptide Antibodies as Probes to Study Interdomain Interactions Involved in Virus Assembly: the Envelope of the Human Immunodeficiency Virus (HIV-1)”, Virology 188:1-13. |
Spalding, B.J., 1992, “In Hot Pursuit of an HIV Vaccine”, Bio/Technology 10:24-29. |
Dubay, J.W. et al., 1991, “Structure-Function Analysis of the HIV Glycoprotein”, Adv. Exp. Med. Biol. 303;39-46. |
ASM News 56:368 (1990). |
Delwart, E.L. and Mosialos, G., 1990, “Retroviral Envelope Glycoproteins Contain a Leucine Zipper-Like Repeat”, AIDS Res. and Human Retroviruses 6:703-706. |
Qureshi, N.M. et al., 1990, “Characterization of a Putative Cellular Receptor for HIV-1 Transmembrane Glycoprotein Using Synthetic Peptides”, AIDS 4:553-558. |
Gallaher, W.R. et al., 1989, “A General Model for the Transmembrane Proteins of HIV and Other Retroviruses”, AIDS Res. and Human Retroviruses 5:431-440. |
Crowl, R. et al., 1985, “HTLV-III env Gene Products Synthesized in E. coli are Recognized by Antibodies Present in the Sera of AIDS Patients”, Cell 41:979-986. |